MDM2 and prostate cancer: For the prostate dataset, Osman et al.[90] hypothesized that a pathway of prostate cancer progression involves p53 inactivation by mdm2 overexpression and that p21 transactivation via an alternative signaling system, rather than through a p53-dependent mechanism.